Scientific Reports (Mar 2021)

Chromosomal translocation t(11;14) and p53 deletion induced by the CRISPR/Cas9 system in normal B cell-derived iPS cells

  • Yusuke Azami,
  • Naohiro Tsuyama,
  • Yu Abe,
  • Misaki Sugai-Takahashi,
  • Ken-ichi Kudo,
  • Akinobu Ota,
  • Karnan Sivasundaram,
  • Moe Muramatsu,
  • Tomonari Shigemura,
  • Megumi Sasatani,
  • Yuko Hashimoto,
  • Shigehira Saji,
  • Kenji Kamiya,
  • Ichiro Hanamura,
  • Takayuki Ikezoe,
  • Masafumi Onodera,
  • Akira Sakai

DOI
https://doi.org/10.1038/s41598-021-84628-5
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Multiple myeloma (MM) cells are derived from mature B cells based on immunoglobulin heavy chain (IgH) gene analysis. The onset of MM is often caused by a reciprocal chromosomal translocation (cTr) between chr 14 with IgH and chr 11 with CCND1. We propose that mature B cells gain potential to transform by reprograming, and then chromosomal aberrations cause the development of abnormal B cells as a myeloma-initiating cell during B cell redifferentiation. To study myeloma-initiating cells, we have already established normal B cell-derived induced pluripotent stem cells (BiPSCs). Here we established two BiPSCs with reciprocal cTr t(11;14) using the CRISPR/Cas9 system; the cleavage site were located in the IgH Eμ region of either the VDJ rearranged allele or non-rearranged allele of IgH and the 5′-upsteam region of the CCND1 (two types of BiPSC13 with t(11;14) and MIB2-6 with t(11;14)). Furthermore, p53 was deleted using the CRISPR/Cas9 system in BiPSC13 with t(11;14). These BiPSCs differentiated into hematopoietic progenitor cells (HPCs). However, unlike cord blood, those HPCs did not differentiated into B lymphocytes by co-culture with BM stromal cell. Therefore, further ingenuity is required to differentiate those BiPSCs-derived HPCs into B lymphocytes.